| abstract |
They are useful as an active ingredient in a medicine for the preventive and / or therapeutic treatment of diseases caused by the abnormal activation of CXCR3 chemokines. This also refers to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to the intermediates used in the preparation of said compounds. Claim 1: A compound of formula (1) wherein R represents hydrogen or a C₁₋₄ alkyl group; R¹ represents a group selected from the group of formulas (2), where R² represents hydrogen or a C₁₋₄ alkyl group; R³ represents hydrogen, halogen, CF₃, CN or C₁₋₄ alkyl; and R⁴ represents hydrogen, halogen or C₁₋₄ alkyl; a = 0, 1 or 2; b = 0, 1, 2 or 3, c = 1, 2 or 3, and Rᵃ, Rᵇ, Rᶜ and Rᵈ independently represent each other H or C₁₋₄ alkyl; X represents an aliphatic hydrocarbon bridge C₂ that optionally contains a double bond or a triple bond or a heteroatom selected from O and S, or -CH (CH₂) CH-; Y represents hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ hydroxyalkyl; Z represents a C₁₋₄ aliphatic hydrocarbon bridge that optionally contains a double bond, and / or one or more heteroatoms selected from O, S, N and N (CH₃) or represents a C₂₋₄ aliphatic hydrocarbon bridge that optionally contains N , fused with a C₃₋₆ cycloalkyl ring that optionally contains one or more double bonds or with a phenyl ring or represents a C₁₋₄ aliphatic hydrocarbon bridge substituted with a C₃₋₆ cycloalkyl spiro ring that optionally contains one or more double bonds; or a pharmaceutically acceptable salt or stereoisomer thereof or a pharmaceutically acceptable salt of the stereoisomer. |